Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

NCT05573893 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05573893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05573893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
September 12, 2023
Completion date
December 31, 2031
Enrollment
800 (estimated)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, neoplasm metastasis